BRD4 inhibitor inhibits colorectal cancer growth and metastasis

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 1928-1948

  Hu, Yuan ^a,b   Zhou, Jieqiong ^a   Ye, Fei ^b   Xiong, Huabao ^b   Peng, Liang ^b   Zheng, Zihan ^c   Xu, Feihong ^b   Cui, Miao ^b   Wei, Chengguo ^b   Wang, Xinying ^a   Wang, Zhongqiu ^a   Zhu, Hongfa ^b   Lee, Peng ^d   Zhou, Mingming ^b   Jiang, Bo ^a   Zhang, David Y ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BRD4; Colorectal cancer; Epithelial to mesenchymal transition (EMT); Metastasis; MS417

Indexed keywords

BROMODOMAIN CONTAINING PROTEIN 2; BROMODOMAIN CONTAINING PROTEIN 4; BROMODOMAIN CONTAINING PROTEIN 4 INHIBITOR; BROMODOMAIN INHIBITOR; FAS ANTIGEN; PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; X LINKED INHIBITOR OF APOPTOSIS; BRD4 PROTEIN, HUMAN; DIBENZAZEPINE DERIVATIVE; MESSENGER RNA; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MALE; METASTASIS; MIDDLE AGED; MOUSE; MRNA EXPRESSION ASSAY; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; NEOPLASM METASTASIS; NUDE MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE; YOUNG ADULT;

ANIMALIA;

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DIBENZAZEPINES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; NUCLEAR PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84921496558     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16011928     Document Type: Article

References (43)

1. Siegel, R.; Desantis, C.; Jemal, A. Colorectal Cancer Statistics, 2014. CA Cancer J. Clin. 2014, 64, 104-117.
2. Klajic, J.; Busato, F.; Edvardsen, H.; Touleimat, N.; Fleischer, T.; Bukholm, I.R.; Borresen-Dale, A.L.; Lonning, P.E.; Tost, J.; Kristensen, V.N. DNA Methylation Status of Key Cell Cycle Regulators such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors. Clin. Cancer Res. 2014, 20, 6357-6366.
3. Alazzam, M.; Tidy, J.; Osborne, R.; Coleman, R.; Hancock, B.W.; Lawrie, T.A. Chemotherapy for Resistant or Recurrent Gestational Trophoblastic Neoplasia. Cochrane Database Syst. Rev. 2012, 12, doi:0.1002/14651858.CD008891.pub2.
4. Holohan, C.; van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer Drug Resistance: An Evolving Paradigm. Nat. Rev. Cancer 2013, 13, 714-726.
5. Grunstein, M. Histone Acetylation in Chromatin Structure and Transcription. Nature 1997, 389, 349-352.
6. Van Engeland, M.; Derks, S.; Smits, K.M.; Meijer, G.A.; Herman, J.G. Colorectal Cancer Epigenetics: Complex Simplicity. J. Clin. Oncol. 2011, 29, 1382-1391.
7. Dhalluin, C.; Carlson, J.E.; Zeng, L.; He, C.; Aggarwal, A.K.; Zhou, M.M. Structure and Ligand of a Histone Acetyltransferase Bromodomain. Nature 1999, 399, 491-496.
8. Mujtaba, S.; Zeng, L.; Zhou, M.M. Structure and Acetyl-Lysine Recognition of the Bromodomain. Oncogene 2007, 26, 5521-5527.
9. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T; et al. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family. Cell 2012, 149, 214-231.
10. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W.B.; Fedorov, O.; Morse, E.M.; Keates, T.; Hickman, T.T.; Felletar, I; et al. Selective Inhibition of BET Bromodomains. Nature 2010, 468, 1067-1073.
11. Mochizuki, K.; Nishiyama, A.; Jang, M.K.; Dey, A.; Ghosh, A.; Tamura, T.; Natsume, H.; Yao, H.; Ozato, K. The Bromodomain Protein BRD4 Stimulates G1 Gene Transcription and Promotes Progression to S Phase. J. Biol. Chem. 2008, 283, 9040-9048.
12. Lenburg, M.E.; Sinha, A.; Faller, D.V.; Denis, G.V. Tumor-Specific and Proliferation-Specific Gene Expression Typifies Murine Transgenic B Cell Lymphomagenesis. J. Biol. Chem. 2007, 282, 4803-4811.
13. French, C.A.; Miyoshi, I.; Kubonishi, I.; Grier, H.E.; Perez-Atayde, A.R.; Fletcher, J.A. BRD4-NUT Fusion Oncogene: A Novel Mechanism in Aggressive Carcinoma. Cancer Res. 2003, 63, 304-307.
14. Thompson-Wicking, K.; Francis, R.W.; Stirnweiss, A.; Ferrari, E.; Welch, M.D.; Baker, E.; Murch, A.R.; Gout, A.M.; Carter, K.W.; Charles, A.K.; et al. Novel BRD4-NUT Fusion Isoforms Increase the Pathogenic Complexity in NUT Midline Carcinoma. Oncogene 2013, 32, 4664-4674.
15. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A.R.; Herrmann, H.; Sison, E.A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; et al. RNAi Screen Identifies Brd4 as a Therapeutic Target in Acute Myeloid Leukaemia. Nature 2011, 478, 524-528.
16. Dawson, M.A.; Prinjha, R.K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W.I.; Robson, S.C.; Chung, C.W.; Hopf, C.; Savitski, M.M.; et al. Inhibition of BET Recruitment to Chromatin as an Effective Treatment for MLL-Fusion Leukaemia. Nature 2011, 478, 529-533.
17. Ceribelli, M.; Kelly, P.N.; Shaffer, A.L.; Wright, G.W.; Xiao, W.; Yang, Y.; Mathews Griner, L.A.; Guha, R.; Shinn, P.; Keller, J.M.; et al. Blockade of Oncogenic IκB Kinase Activity in Diffuse Large B-Cell Lymphoma by Bromodomain and Extraterminal Domain Protein Inhibitors. Proc. Natl. Acad. Sci. USA 2014, 111, 11365-11370.
18. Mertz, J.A.; Conery, A.R.; Bryant, B.M.; Sandy, P.; Balasubramanian, S.; Mele, D.A.; Bergeron, L.; Sims, R.J. Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains. Proc. Natl. Acad. Sci. USA 2011, 108, 16669-16674.
19. Shimamura, T.; Chen, Z.; Soucheray, M.; Carretero, J.; Kikuchi, E.; Tchaicha, J.H.; Gao, Y.; Cheng, K.A.; Cohoon, T.J.; Qi, J.; et al. Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer. Clin. Cancer Res. 2013, 19, 6183-6192.
20. Crawford, N.P.; Alsarraj, J.; Lukes, L.; Walker, R.C.; Officewala, J.S.; Yang, H.H.; Lee, M.P.; Ozato, K.; Hunter, K.W. Bromodomain 4 Activation Predicts Breast Cancer Survival. Proc. Natl. Acad. Sci. USA 2008, 105, 6380-6385.
21. Alsarraj, J.; Walker, R.C.; Webster, J.D.; Geiger, T.R.; Crawford, N.P.; Simpson, R.M.; Ozato, K.; Hunter, K.W. Deletion of the Proline-Rich Region of the Murine Metastasis Susceptibility Gene Brd4 Promotes Epithelial-to-Mesenchymal Transition- and Stem Cell-Like Conversion. Cancer Res. 2011, 71, 3121-3131.
22. Alsarraj, J.; Faraji, F.; Geiger, T.R.; Mattaini, K.R.; Williams, M.; Wu, J.; Ha, N.H.; Merlino, T.; Walker, R.C.; Bosley, A.D.; et al. BRD4 Short Isoform Interacts with RRP1B, SIPA1 and Components of the LINC Complex at the Inner Face of the Nuclear Membrane. PLoS One 2013, 8, e80746.
23. Segura, M.F.; Fontanals-Cirera, B.; Gaziel-Sovran, A.; Guijarro, M.V.; Hanniford, D.; Zhang, G.; Gonzalez-Gomez, P.; Morante, M.; Jubierre, L.; Zhang, W.; et al. BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy. Cancer Res. 2013, 73, 6264-6276.
24. Floyd, S.R.; Pacold, M.E.; Huang, Q.; Clarke, S.M.; Lam, F.C.; Cannell, I.G.; Bryson, B.D.; Rameseder, J.; Lee, M.J.; Blake, E.J.; et al. The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signalling. Nature 2013, 498, 246-250.
25. Sahai, V.; Kumar, K.; Knab, L.M.; Chow, C.R.; Raza, S.S.; Bentrem, D.J.; Ebine, K.; Munshi, H.G. BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen. Mol. Cancer Ther. 2014, 13, 1907-1917.
26. Rodriguez, R.M.; Huidobro, C.; Urdinguio, R.G.; Mangas, C.; Soldevilla, B.; Dominguez, G.; Bonilla, F.; Fernandez, A.F.; Fraga, M.F. Aberrant Epigenetic Regulation of Bromodomain BRD4 in Human Colon Cancer. J. Mol. Med. 2012, 90, 587-595.
27. Zhang, G.; Liu, R.; Zhong, Y.; Plotnikov, A.N.; Zhang, W.; Zeng, L.; Rusinova, E.; Gerona-Nevarro, G.; Moshkina, N.; Joshua, J.; et al. Down-Regulation of NF-κB Transcriptional Activity in HIV-Associated Kidney Disease by BRD4 Inhibition. J. Biol. Chem. 2012, 287, 28840-28851.
28. Boehm, D.; Calvanese, V.; Dar, R.D.; Xing, S.; Schroeder, S.; Martins, L.; Aull, K.; Li, P.C.; Planelles, V.; Bradner, J.E.; et al. BET Bromodomain-Targeting Compounds Reactivate HIV from Latency Via a Tat-Independent Mechanism. Cell Cycle 2013, 12, 452-462.
29. Liu, R.; Zhong, Y.; Li, X.; Chen, H.; Jim, B.; Zhou, M.M.; Chuang, P.Y.; He, J.C. Role of Transcription Factor Acetylation in Diabetic Kidney Disease. Diabetes 2014, 63, 2440-2453.
30. Lavilla-Alonso, S.; Abo-Ramadan, U.; Halavaara, J.; Escutenaire, S.; Tatlisumak, T.; Saksela, K.; Kanerva, A.; Hemminki, A.; Pesonen, S. Optimized Mouse Model for the Imaging of Tumor Metastasis upon Experimental Therapy. PLoS One 2011, 6, e26810.
31. Maamer-Azzabi, A.; Ndozangue-Touriguine, O.; Breard, J. Metastatic SW620 Colon Cancer Cells are Primed for Death when Detached and can be Sensitized to Anoikis by the BH3-Mimetic ABT-737. Cell. Death Dis. 2013, 4, doi:10.1038/cddis.2013.328.
32. Wu, S.Y.; Chiang, C.M. The Double Bromodomain-Containing Chromatin Adaptor Brd4 and Transcriptional Regulation. J. Biol. Chem. 2007, 282, 13141-13145.
33. Yang, Z.; He, N.; Zhou, Q. Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis to Promote G1 Gene Expression and Cell Cycle Progression. Mol. Cell. Biol. 2008, 28, 967-976.
34. Itzen, F.; Greifenberg, A.K.; Bosken, C.A.; Geyer, M. Brd4 Activates P-TEFb for RNA Polymerase II CTD Phosphorylation. Nucleic Acids Res. 2014, 42, 7577-7590.
35. Nishiyama, A.; Dey, A.; Miyazaki, J.; Ozato, K. Brd4 is Required for Recovery from Antimicrotubule Drug-Induced Mitotic Arrest: Preservation of Acetylated Chromatin. Mol. Biol. Cell 2006, 17, 814-823.
36. Williams, C.S.; Zhang, B.; Smith, J.J.; Jayagopal, A.; Barrett, C.W.; Pino, C.; Russ, P.; Presley, S.H.; Peng, D.; Rosenblatt, D.O.; et al. BVES Regulates EMT in Human Corneal and Colon Cancer Cells and Is Silenced via Promoter Methylation in Human Colorectal Carcinoma. J. Clin. Investig. 2011, 121, 4056-4069.
37. Shi, J.; Wang, Y.; Zeng, L.; Wu, Y.; Deng, J.; Zhang, Q.; Lin, Y.; Li, J.; Kang, T.; Tao, M.; et al. Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-Like Breast Cancer. Cancer Cell 2014, 25, 210-225.
38. Barrallo-Gimeno, A.; Nieto, M.A. The Snail Genes as Inducers of Cell Movement and Survival: Implications in Development and Cancer. Development 2005, 132, 3151-3161.
39. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; et al. The EMT-Activator ZEB1 Promotes Tumorigenicity by Repressing Stemness-Inhibiting microRNAs. Nat. Cell Biol. 2009, 11, 1487-1495.
40. Fotoohi, K.; Jansen, G.; Assaraf, Y.G.; Rothem, L.; Stark, M.; Kathmann, I.; Gregorczyk, J.; Peters, G.J.; Albertioni, F. Disparate Mechanisms of Antifolate Resistance Provoked by Methotrexate and its Metabolite 7-Hydroxymethotrexate in Leukemia Cells: Implications for Efficacy of Methotrexate Therapy. Blood 2004, 104, 4194-4201.
41. Yurgel, V.C.; Oliveira, C.P.; Begnini, K.R.; Schultze, E.; Thurow, H.S.; Leon, P.M.; Dellagostin, O.A.; Campos, V.F.; Beck, R.C.; Guterres, S.S.; et al. Methotrexate Diethyl Ester-Loaded Lipid-Core Nanocapsules in Aqueous Solution Increased Antineoplastic Effects in Resistant Breast Cancer Cell Line. Int. J. Nanomed. 2014, 9, 1583-1591.
42. Wang, T.P.; Hsu, S.H.; Feng, H.C.; Huang, R.F. Folate Deprivation Enhances Invasiveness of Human Colon Cancer Cells Mediated by Activation of Sonic Hedgehog Signaling through Promoter Hypomethylation and Cross Action with Transcription Nuclear Factor-κB Pathway. Carcinogenesis 2012, 33, 1158-1168.
43. Yang, Y.I.; Ahn, J.H.; Lee, K.T.; Shih, I.; Choi, J.H. RSF1 is a Positive Regulator of NF-κB-Induced Gene Expression Required for Ovarian Cancer Chemoresistance. Cancer Res. 2014, 74, 2258-2269.